Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

NCT01237067 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

NIH

Sponsor class

Conditions

Ovarian Cancer
Breast Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Endometrial Cancer

Interventions

DRUG: Carboplatin
DRUG: Olaparib

Sponsor

National Cancer Institute (NCI)